Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
 & Lead Plaintiff Deadline: October 31, 2016 - EconoTimes)
NEW YORK, Sept. 19, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against American Renal Associates Holdings, Inc. (“American Renal Associates” or the “Company”) (NYSE:ARA) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased American Renal Associates securities: (1) pursuant and/or traceable to American Renal’s Initial Public Offering on or about April 21, 2016 (the “IPO”); and/or (2) from April 21, 2016 through August 18, 2016, inclusive (the “Class Period”).
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) American Renal was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for American Renal’s dialysis services; (2) the foregoing scheme was in violation of federal and state laws; and (3) as a result, American Renal’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ara or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in American Renal Associates you have until October 31, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
